MPX Bioceutical to acquire Canveda for $18M
MPX Bioceutical (CSE: MPX, OTC: MPXEF) to acquire 100% of the issued and outstanding shares of Canveda Inc. for a total purchase price of CDN $18 million
Cannabis/Marijuana
Cannex Capital to acquire Ametrine Wellness/Jetty Extracts
Cannex Capital Holdings Inc. (CSE: CNNX) signed a binding letter agreement to acquire 100% of Oakland, California based Ametrine Wellness Inc. dba Jetty Extracts
Cannabis Wheaton Income to acquire Robinson’s Cannabis
Cannabis Wheaton Income (TSX-V: CBW) to acquire all of the issued and outstanding shares of Robinson’s Cannabis Incorporated in an all-stock transaction
Aphria completes acquisition of Nuuvera
Aphria (TSX: APH; OTC: APHQF) closed acquisition of Nuuvera (TSX-V: NUU). Former Nuuvera shareholder will receive $0.62 in cash, rather than $0.60, as previously announced, plus 0.3546 of a common share of Aphria, for each Nuuvera share held
Xanthic Biopharma announces $1.5M private placement
Xanthic Biopharma Inc., formerly Aurquest Resources Inc, to close a non-brokered private placement of up to 3M units at $0.50 for gross proceeds of up to $1.5M
High Hampton Holdings closes $19 M private placement
High Hampton Holdings Corp. (CSE: HC; FSE: 0HCN) closed a non-brokered private placement of 31,703,565 units at $0.60 for gross proceeds of approximately $19 million.
BELGRAVIA CAPITAL to invest $1M in R&D Pharma Corp
BELGRAVIA CAPITAL INTERNATIONAL INC. (CSE: BLGV; OTCQB: BLGVF) to invest $1M in R&D Pharma Corp. at a price of $0.25 per common share
Nuuvera acquires ASG Pharma
Nuuvera (TSX-V: NUU) acquired ASG Pharma, a high-capacity Maltese GMP laboratory that is expected to be one of Nuuvera’s hubs for the production and distribution of oil-based medical cannabis products to the emerging European medical cannabis market.
Aphria closes $217M acquisition of Broken Coast Cannabis
Aphria Inc. (TSX: APH; OTC: APHQF) completed acquisition of Broken Coast Cannabis Inc. for $217M, through issuance to the vendors of 14,373,675 common shares
Emerald Health Therapeutics announces $18M financing and $12M secondary sale
Emerald Health Therapeutics (TSX-V: EMH) entered into a binding term sheet with a single Canadian institutional accredited investor for the sale of 3M units at $6.00 for gross proceeds of $18M
